Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCCAM

This article was originally published in The Tan Sheet

Executive Summary

NIH center seeks applications to characterize standardized versions of echinacea, feverfew, milk thistle and valerian root. The grantees also would be required to develop the capability to provide the standardized botanicals for NIH-sponsored trials, the RFA states. One award will be made for each herb, with awards totaling $6 mil. over three years. NCCAM's advisory council unanimously approved the initiative in January (1"The Tan Sheet" Jan. 31, p. 6). Letters of intent are due by Sept. 7, the application deadline is Nov. 14

You may also be interested in...



Herbal Standardization Initiative Approved By NCCAM Advisory Council

The National Advisory Council for Complementary & Alternative Medicine unanimously approved an initiative to characterize standardized versions of echinacea, feverfew, milk thistle and valerian root that could be used in Phase II/III clinical trials. The initiative, entitled "Natural Products Development," was discussed at a meeting held Jan. 24-25 in Rockville, Md.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS091408

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel